Radiosensitization by a new nucleoside analogue: 1-[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl-2-nitroimidazole (RP-170)

This publication has 24 references indexed in Scilit:

• Phase I trial of the hypoxic cell radiosensitizer SR-2508: The results of the five to six week drug schedule
  International Journal of Radiation Oncology*Biology*Physics, 1986
• Synthesis of 9-(4-hydroxy-2-oxobutyl)guanine, 9-(2,4-dihydroxybutyl)guanine and related acyclic nucleoside analogs
  The Journal of Organic Chemistry, 1985
• Radiosensitizers: A conference preview
  International Journal of Radiation Oncology*Biology*Physics, 1984
• In vitro and in vivo radiosensitization by 2-nitroimidazoles more electron-affinic than misonidazole
  International Journal of Radiation Oncology*Biology*Physics, 1982
• A new potent radiosensitizer: 1-(2′, 3′-dideoky-α-d-erythro-hex-2′-enopyranosyl)-2-nitroimidazole (RA-263)
  International Journal of Radiation Oncology*Biology*Physics, 1982
• The development of an oral prodrug, SR-2545, of the 2-nitroimidazole radiosensitizer SR-2508
  International Journal of Radiation Oncology*Biology*Physics, 1982
• SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use
  International Journal of Radiation Oncology*Biology*Physics, 1981
• The optimum time for irradiation relative to tumour concentration of hypoxic cell sensitizers
  The British Journal of Radiology, 1980
• Mechanism of Action of Nitroimidazole Antimicrobial and Antitumour Radiosensitizing Drugs
  International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine, 1979
• A New Substituent Constant, π, Derived from Partition Coefficients
  Journal of the American Chemical Society, 1964